PDX and Genomic Medicine

Cancer is a heterogeneous disease caused by diverse genomic alterations in oncogenes and tumor suppressor genes. Despite recent advances in high-throughput sequencing technologies and development of targeted therapies, novel cancer drug development is limited due to the high attrition rate from clinical studies. Patient-derived xenografts (PDX), which are established by the transfer of patient tumors into immunodeficient mice, serve as a platform for co-clinical trials by enabling the integration of clinical data, genomic profiles, and drug responsiveness data to determine precisely targeted therapies. PDX models retain many of the key characteristics of patients’ tumors including histology, genomic signature, cellular heterogeneity, and drug responsiveness. These models can also be applied to the development of biomarkers for drug responsiveness and personalized drug selection. This seminar summarizes our current knowledge of this field, including methodologic aspects, applications in drug development, challenges and limitations, and utilization for precision cancer medicine.

Hansoo Park, M.D. & Ph.D.

1998         Seoul National University School of Medicine, Korea, M.D.

1999 – 2001   Seoul National University School of Medicine, Department of Biochemistry, Korea, M.S.

2001 – 2007   Seoul National University School of Medicine, Department of Biochemistry, Korea, Ph.D.

2009 – 2013   Harvard Medical School, Brigham & Women’s Hospital; Research Associate

2013 – 2016   The Jackson Laboratory for Genomic Medicine; Research Associate

2016   Ewha Womans University; Assistant Professor

2016 – Present Gwangju Institute of Science and Technology; Assistant Professor

Specialty and Present Interest:

Genomic Medicine, Patient Derived Xenograft (PDX)

Phone: +82 2 3277 6819

E-mail: ,